Retina

Aleksandra Rachitskaya, MD, discusses how the treatment landscape for inherited retinal diseases has changed and her hope for the future.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular oedema.

Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks, however it was safe and well tolerated with no new or unexpected safety signals.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.

Tiffani Martin was diagnosed with type 1 juvenile diabetes when she was just 5 years old, and has battled myriad health issues as a result, including vision loss. Leading the charge for a multifactorial approach to combat diabetes, Kristen Nwanyanwu, MD, MBA, MHS, and her team have embraced the need for a multi-pronged program to address health disparities in diabetic retinopathy.

Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

The company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

Kato Pharmaceuticals will study the efficacy of Resolv ER for the treatment of vitreomacular attachment.

According to data presented by Horizon Therapeutics at the North American Neuro-Ophthalmology Society annual meeting held this week in Austin, Texas, Uplizna treatment is linked to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo.

Novel treatment reduces treatment burden and improves outcomes.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer’s, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.

At Angiogenesis, Dr David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

According to the company, it is developing elamipretide for treatment of extra-foveal GA under U.S. FDA Fast Track designation.

AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.

During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.

Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.

A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.

Dr. Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.